Pharmacists in Haysville, KS Accepting Medicare
3 Pharmacists found. Showing 1 - 3
 Christopher D Benest, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 N Main St, Haysville, KS 67060 Phone: 316-522-5583 Fax: 316-524-4197 |
Dr. Michael Fillmore, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 N Main St, Haysville, KS 67060 Phone: 316-522-5580 Fax: 316-524-4197 |
Rex Parish, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 201 N Main St, Haysville, KS 67060 Phone: 316-522-5583 Fax: 316-524-4197 |
News Archive
Canadian Court to determine constitutionality of law preventing supervised drug-injection sites
The British Columbia Court of Appeals this week is hearing a case to decide whether certain sections of Canada's Controlled Drugs and Substances Act that prevent injection drug users from accessing services at the supervised drug-injection facility Insite in Vancouver, British Columbia, are constitutional, Toronto's Globe and Mail reports (Stueck, Globe and Mail, 4/28).
Intermittent fasting shown to improve blood glucose levels
Researchers have shown that fasting can improve glycemic (blood sugar) responses in men with a high risk of developing diabetes, irrespective of how much food they eat.
Gadolinium-enhanced MRI of shoulders helps predict recurrence of polymyalgia rheumatica
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.
Onyx announces results from regorafenib Phase 3 trial on GIST
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
EPO approves Advaxis patent application for Listeria Antigens
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled "Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens," has been granted and will be issued as patent #1032417
› Verified 6 days ago
Dentists
Occupational Therapists
Psychologists
Pharmacists
Counselors
Clinical Social Workers
Marriage Counselors